The therapeutic monoclonal antibody market

MAbs. 2015;7(1):9-14. doi: 10.4161/19420862.2015.989042.


Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use*
  • Drug Approval*
  • Europe
  • Humans
  • Marketing*
  • United States


  • Antibodies, Monoclonal